Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 14(2): e0212036, 2019.
Article in English | MEDLINE | ID: mdl-30742668

ABSTRACT

BACKGROUND: Non-invasive methods are the first choice for liver fibrosis evaluation in chronic liver diseases, but few studies investigate the ability of combined methods to predict outcomes. METHODS: 591 chronic hepatitis C patients with baseline liver stiffness (LSM) by FibroScan and hyaluronic acid measurements were identified retrospectively. The patients were grouped by baseline LSM: < 10kPa, 10-16.9kPa, and 17-75kPa. Primary outcomes were all-cause mortality and liver-related mortality, analyzed using cox regression and competing risk regression models, respectively. RESULTS: Median follow-up was 46.1 months. Prevalence of cirrhosis at baseline was 107/591 (18.1%). Median LSM was 6.8kPa (IQR 5.3-11.6) and divided into groups, 404/591 (68.4%) had a LSM < 10kPa, 100/591 (16.9%) had a LSM between 10-16.9kPa and 87/591 (14.7%) had a LSM between 17-75kPa. There were 69 deaths, 27 from liver-related disease. 26 patients developed cirrhosis and 30 developed complications of cirrhosis. The mortality rate in the 17-75kPa group was 9.7/100 person-years, compared to 2.2/100 person-years and 1.1/100 person-years in the 10-16.9kPa and <10kPa groups (p<0.005). Liver-related mortality increased 10-fold for each group (p<0.005). Cirrhotic complications occurred almost exclusively in the 17-75kPa group, with an incidence of 10.3/100 person-years, compared to 1.8/100 person-years and 0.2/100 person-years in the 10-16.9kPa and <10kPa groups (p<0.005). Median hyaluronic acid in the 17-75kPa group was approximately 200ng/mL. Patients with a LSM 17-75kPa had significantly higher risks of death, liver-related death, and complications to cirrhosis if their hyaluronic acid measurement was more than or equal to 200ng/mL at baseline, with hazard ratios of 3.25 (95% CI 1.48-7.25), 7.7 (95% CI 2.32-28), and 3.2 (95% CI 1.35-7.39), respectively. CONCLUSIONS: The combination of LSM and circulating hyaluronic acid measurements significantly improved prognostic ability, relative to LSM alone. Combined static and dynamic markers of liver fibrosis could provide superior risk prediction.


Subject(s)
Hepatitis C, Chronic/mortality , Hyaluronic Acid/blood , Liver Cirrhosis/epidemiology , Liver/pathology , Adult , Elasticity Imaging Techniques , Female , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/metabolism , Humans , Liver/diagnostic imaging , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/metabolism , Liver Cirrhosis/mortality , Male , Middle Aged , Prevalence , Prognosis , Regression Analysis , Retrospective Studies
2.
PLoS One ; 7(9): e45181, 2012.
Article in English | MEDLINE | ID: mdl-23024806

ABSTRACT

The chemokine IP-10 (CXCL10) is a candidate marker for hepatitis C virus (HCV) fibrosis monitoring. The aim of this proof-of-concept study is to assess if IP-10 measurements from dried plasma spots (DPS) are accurate in HCV-infected patients with either minimal or significant fibrosis. We measured IP-10 levels in plasma and DPS of 21 HCV-infected patients with cirrhosis and 19 patients with no/little fibrosis (determined with FibroScan). Cirrhotic patients had significantly higher levels of IP-10 compared to patients with minimal fibrosis. DPS and plasma measurements of IP-10 are comparable and the correlation was excellent (r(2) = 0.97, p<0.0001). The DPS based method for IP-10 detection performs well in HCV-infected patients with either minimal or significant fibrosis.


Subject(s)
Chemokine CXCL10/blood , Dried Blood Spot Testing , Hepatitis C, Chronic/diagnosis , Adult , Aged , Biomarkers/blood , Female , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/complications , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/diagnosis , Liver Cirrhosis/etiology , Male , Middle Aged , ROC Curve
3.
Eur J Gastroenterol Hepatol ; 23(1): 41-4, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21079513

ABSTRACT

OBJECTIVE: Transient elastography (TE) is a noninvasive and well validated method for measurement of liver stiffness. The aim of this study was to use TE to evaluate whether patients with sustained virological response (SVR) have lower liver stiffness than patients with non-SVR after treatment for chronic hepatitis C (CHC). METHODS: Patients with CHC, who had undergone liver biopsy before treatment with pegylated interferon and ribavirin, were included from four clinical centres in Denmark. All patients were examined with TE and had a blood test taken for hepatitis C virus-virus detection and analysis of alanine aminotransferase, platelet counts and hyaluronic acid. RESULTS: For 110 (92%) of the 120 patients included, it was possible to obtain a successful measurement of liver stiffness. Of these, 71 (64.5%) had achieved SVR. Median follow-up time was 47 months. Patients with pretreatment minimal fibrosis (F0/F1) in their liver biopsy had median liver stiffness of 5.3 kPa for SVR versus 6.1 kPa for non-SVR (P=0.56). Patients with pretreatment moderate fibrosis (F2/F3) had median liver stiffness of 5.4 kPa for SVR versus 9.4 kPa for non-SVR (P<0.001). Median liver stiffness for patients with pretreatment cirrhosis (F4) was 6.8 kPa for SVR versus 24 kPa for non-SVR (P<0.001). CONCLUSIONS: Examination with TE 4 years after treatment shows that patients with CHC, who have achieved SVR, have significantly lower liver stiffness than patients with non-SVR. This indicates that histological liver outcome improves during the first year after the treatment for CHC.


Subject(s)
Antiviral Agents/therapeutic use , Elasticity Imaging Techniques , Hepacivirus/drug effects , Hepatitis C, Chronic/diagnostic imaging , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/diagnostic imaging , Liver/diagnostic imaging , Alanine Transaminase/blood , Cohort Studies , Denmark , Female , Hepacivirus/isolation & purification , Hepatitis C, Chronic/pathology , Humans , Hyaluronic Acid/blood , Interferon alpha-2 , Interferon-alpha/therapeutic use , Liver/pathology , Liver Cirrhosis/pathology , Male , Middle Aged , Platelet Count , Polyethylene Glycols/therapeutic use , Recombinant Proteins , Ribavirin/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...